Share performance
Puleva Biotech’s shares were not immune to the widespread equity rout experienced throughout 2008, notably during the second half of the year.
Nonetheless, as depicted in the accompanying chart, the stock outperformed the Ibex small caps index, although the bear market of the final weeks of the year levelled the playing field, bringing all stocks a down.
Share price recovery
Puleva Biotech has the advantage of being able to provide tailored solutions
The stock is unlikely to recover until the worst of the financial storm has passed. However, the Company’s fundamentals point to scope for significant upside once the unfolding international crisis begins to wane.
The new Puleva Biotech is underpinned by a new biotechnology research approach, based on applied research focused on vale added products which, added to food and nutritional substances, generate positive returns over a short investment horizon.
Applied research
The trend is one of compressed timeframes to monetise research by involving all the elements of the company’s value chain. This means research applied to consumers’ actual requirements, turning a profit in the short term, and enabling funding for high value added research initiatives that require longer investment cycles.
This new model will enable sustainable revenue growth which, framed by the sales capacity built up and Group synergies, will add substance to the Company’s valuation.
Shareholder care
Puleva Biotech has permanent open lines with its shareholders, who are kept abreast of the Company’s performance through its quarterly earnings releases and the significant event notifications filed with Spanish securities market watchdog, the CNMV.
The Shareholder Office can be reached by investors at:
www.pulevabiotech.es
oficinaatencionaccionista@pulevabiotech.es
Telephone: +34 958 240 200
| Number of shares outstanding | 57,699,522 |
|---|---|
| Price (€ per share) | 0.89 |
| Market value (€) | 51,352,574 |
| Ebro Puleva Group | 51.020% |
|---|---|
| Pescaderías Coruñesas | 5.061% |
| Exxentia Sellers | 11.09% |
Share price perfomance
Share price on 28/12/2007 2.12€
Share price on 31/12/2008 0.89€
